Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -34.79% is 22% above its 5-year average of -44.81%, around the middle of its 5-year range (-57.93%–-22.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 31.14% above its 12-month average of -50.51%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -34.79%.
RETURN ON INVESTED CAPITAL (ROIC)
-34.79%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-50.51%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-52.89%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-44.81%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+31.14%
CURRENT VS 3Y AVG
+34.22%
CURRENT VS 5Y AVG
+22.38%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-27.33%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-27.28%
vs the sector median at left
Allogene Therapeutics, Inc.
Market Cap
$517.73M
Return on Invested Capital (ROIC)
-34.79%
TTM Avg
-50.51%
3Y Avg
-52.89%
5Y Avg
-44.81%
Market Cap
$517.79M
Return on Invested Capital (ROIC)
-102.59%
TTM Avg
-133.31%
3Y Avg
-119.78%
5Y Avg
-99.25%
Market Cap
$519.25M
Return on Invested Capital (ROIC)
-19.47%
TTM Avg
-57.88%
3Y Avg
-52.57%
5Y Avg
-47.02%
Market Cap
$491.93M
Return on Invested Capital (ROIC)
-15.54%
TTM Avg
-22.63%
3Y Avg
-32.48%
5Y Avg
-46.23%
Market Cap
$491.55M
Return on Invested Capital (ROIC)
-5.29%
TTM Avg
-5.58%
3Y Avg
-6.88%
5Y Avg
-5.95%
Market Cap
$547.86M
Return on Invested Capital (ROIC)
-0.81%
TTM Avg
-8.59%
3Y Avg
-110.96%
5Y Avg
-102.03%
Market Cap
$487.30M
Return on Invested Capital (ROIC)
-13.15%
TTM Avg
-33.80%
3Y Avg
-80.16%
5Y Avg
-71.70%
Market Cap
$551.09M
Return on Invested Capital (ROIC)
-18.20%
TTM Avg
-95.31%
3Y Avg
-87.63%
5Y Avg
-71.60%
Market Cap
$481.33M
Return on Invested Capital (ROIC)
-2.19%
TTM Avg
-24.50%
3Y Avg
-28.59%
5Y Avg
-24.45%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $517.73M | -34.79% | -50.51% | -52.89% | -44.81% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -102.59% | -133.31% | -119.78% | -99.25% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -19.47% | -57.88% | -52.57% | -47.02% |
| Evolus, Inc. (EOLS)vs › | $491.93M | -15.54% | -22.63% | -32.48% | -46.23% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -5.29% | -5.58% | -6.88% | -5.95% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | -0.81% | -8.59% | -110.96% | -102.03% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | -13.15% | -33.80% | -80.16% | -71.70% |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | -18.20% | -95.31% | -87.63% | -71.60% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | -2.19% | -24.50% | -28.59% | -24.45% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -27.22% | -25.30% | -27.88% | -30.72% |
ROIC
-34.8%
ROE
-37.9%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -34.79% |
| 2026-03-31 | -50.58% |
| 2025-12-31 | -54.60% |
| 2025-09-30 | -54.67% |
| 2025-06-30 | -57.93% |
| 2025-03-31 | -56.26% |
| 2024-12-31 | -53.24% |
| 2024-09-30 | -53.52% |
| 2024-06-30 | -46.87% |
| 2024-03-31 | -53.03% |
| 2023-12-31 | -54.11% |
| 2023-09-30 | -49.76% |
| 2023-06-30 | -50.05% |
| 2023-03-31 | -51.59% |
| 2022-12-31 | -43.69% |
| 2022-09-30 | -37.32% |
| 2022-06-30 | -34.14% |
| 2022-03-31 | -32.61% |
| 2021-12-31 | -25.50% |
| 2021-09-30 | -24.50% |
| 2021-06-30 | -22.36% |
| 2021-03-31 | -20.79% |
| 2020-12-31 | -22.78% |
| 2020-09-30 | -21.62% |
| 2020-06-30 | -19.75% |
| 2020-03-31 | -33.74% |
| 2019-12-31 | -29.50% |
| 2019-09-30 | -25.74% |
| 2019-06-30 | -19.78% |
| 2019-03-31 | -31.40% |
| 2018-12-31 | -25.91% |
| 2018-09-30 | -38.47% |
